drugset / Trial / NCT05753722
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
Timeline
- Start
- 2023-03-03
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRTH-101 | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |